A Gran Fondo rider has tested positive for a drug not approved for human consumption after being withdrawn from testing when it caused cancer in rats.
The positive result was detected during tests carried out by Grand Fondo NY Cozumel in Mexico last month.
“Rudy Rincon tested positive for GW1516 during out-of-competition controls conducted in concurrence with the 2019 GFNY Cozumel, which was held on November 10th,” event organisers GFNY said in a statement.
“Rincon has been disqualified from GFNY Cozumel and
receives a lifetime ban from all GFNY events.
“Rincon was among several randomly selected athletes out
of a testing pool of 40, which contained riders with a legitimate chance to
place in the top 10 overall or win an age group.”
“GW1516, also known as Endurobol on the black market, is
a fat-burning pill that initial trials suggested could increase stamina and
help lose weight.
Advertisement
Related News
“However, GW1516 was pulled from clinical trials
when it was found to rapidly develop cancer in several organs of test rats.
“Because it was not approved for human use, it has not undergone human studies and is not safe to use.”
GFNY introduced doping controls in 2012 when David Anthony (USA) and Gabriele Guarini (Italy) tested positive for EPO at GFNY after winning their age groups.
In 2015 overall winner Oscar Tovar (Colombia) and women’s 3rd place rider Yamile Lugo (Colombia) tested positive for testosterone.
Two years ago Manuel Serrano Plowells (Mexico) tested positive
for EPO as did Gabriel Raff (Argentina) and Felipe Mendez (Colombia) this year
in tests run around GFNY events.
GFNY is a global Gran Fondo company with events held in New
York City, Argentina, Bali, Chile, Colombia, Costa Rica, Ecuador, France,
Italy, Israel, Mexico, Mexico, Panama, Philippines, Portugal, Dominican
Republic, Santa Fe USA and Uruguay.
Topics
